Last Updated : July 26, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Onivyde | Nanoliposomal Irinotecan | Cancelled | ||||
| Cyramza | Ramucirumab | Cancelled | ||||
| Imbruvica | ibrutinib | Leukemia | Canada’s Drug Agency is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| Oncaspar | pegaspargase | Adult Acute Lymphocytic Leukemia (ALL) | Canada’s Drug Agency is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| Revolade | eltrombopag | Severe aplastic anemia | Canada’s Drug Agency is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| Viibryd | vilazodone | Depression, Major depressive disorder | Canada’s Drug Agency is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| Erbitux | Cetuximab | Cancelled | ||||
| Atriance | Nelarabine | Cancelled | ||||
| Admelog | Insulin lispro | Cancelled | ||||
| TBD | Rituximab | Cancelled | ||||
| Translarna | ataluren | Cancelled | ||||
| TBD | Trastuzumab | Cancelled | ||||
| Truxima | Rituximab | Cancelled | ||||
| Xeljanz | tofacitinib | Cancelled | ||||
| TBC | filgrastim | Cancelled | ||||
| Adcetris | brentuximab vedotin | Hodgkin lymphoma | Withdrawn | |||
| N/A | dimethyl fumarate | Multiple Sclerosis (MS) | Pending | |||
| N/A | teriflunomide | Multiple Sclerosis (MS) | Pending | |||
| TBC | tarlatamab | Extensive stage small cell lung cancer | Pending | |||
| TBD | iptacopan | paroxysmal nocturnal hemoglobinuria (PNH) | Pending | |||
| Jemperli | dostarlimab | Endometrial cancer | Pending | |||
| TBC | garadacimab | Hereditary angioedema (HAE) | Pending | |||
| TBC | donanemab | Alzheimer’s disease | Pending | |||
| Winlevi | clascoterone | Acne vulgaris | Pending | |||
| TBC | rozanolixizumab | Generalized myasthenia gravis (gMG). | Pending |
Last Updated : July 26, 2024